Recon: Boehringer slated to cap asthma inhaler costs at $35 a month; Novo surges on early-stage obesity drug data
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States